
NASDAQHealthcareMedical - Devices
ข้อมูลล่าสุด
US$58.84
+US$0.92 · +1.59%
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
ราคาปิดก่อนหน้า
US$58.84
+US$0.92 · +1.59%
หลังปิดตลาด
US$58.84
US$0.00 · 0.00%
9 ต.ค. 19:30 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$58.84
ช่วง 52 สัปดาห์
ปัจจุบัน US$58.84
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ขาย
มูลค่า
18
ราคาสูงเกินไป
ความเชื่อมั่น
60
ผสม
ความเสี่ยง
44
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
61
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$58.84
ช่วง 52 สัปดาห์
ปัจจุบัน US$58.84
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 3.44B USD | 3.37B USD | 2.96B USD | 2.53B USD | 2.42B USD |
| ต้นทุนสินค้าขาย | 1.86B USD | 1.72B USD | 1.45B USD | 1.23B USD | 1.21B USD |
| กำไรขั้นต้น | 1.58B USD | 1.65B USD | 1.51B USD | 1.31B USD | 1.21B USD |
| การวิจัยและพัฒนา | 395.2M USD | 376.5M USD | 294.8M USD | 235.9M USD | 220.8M USD |
| การขาย ทั่วไป และธุรการ | 946.5M USD | 893.8M USD | 729.4M USD | 607.4M USD | 562.3M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 1.34B USD | 1.4B USD | 1.08B USD | 873M USD | 796.3M USD |
| รายได้ดอกเบี้ย | 14.8M USD | 9.3M USD | 7.5M USD | 2.8M USD | 900K USD |
| ดอกเบี้ยจ่าย | 60.3M USD | 47.9M USD | 16.4M USD | 16.1M USD | 14.3M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 220.3M USD | 183.8M USD | 114.9M USD | 88.7M USD | 89.1M USD |
| รายได้จากการดำเนินงาน | 236M USD | 253.1M USD | 436.9M USD | 432.7M USD | 413.3M USD |
| รายได้สุทธิ | −8.6M USD | 113.1M USD | 427.2M USD | 296.6M USD | 277.1M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 10 ต.ค. 2569.
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ผลที่ประกาศแล้วพร้อมประมาณการร่วมที่มีอยู่
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI196.51M0.01%2.3T USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB142.29M0.08%185.3B USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR90.32M0.13%68.2B USD0.05%US$234.43+0.22%
First Trust NYSE Arca Biotechnology Index FundFBT87.31M3.08%2.84B USD0.55%US$265.4+2.00%
Vanguard Extended Market ETFVXF74.93M0.08%95.4B USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS61.71M0.18%33.87B USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB49.83M0.47%10.28B USD0.44%US$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY47.76M0.19%25.58B USD0.23%US$669.87+0.54%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
First Trust NYSE Arca Biotechnology Index FundFBT
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
iShares Biotechnology ETFIBB
State Street SPDR S&P MIDCAP 400 ETF TrustMDYเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน